Drug intelligence / Profile preview

lactobacillus fermentum LF61 + lactobacillus acidophilus LA85 + lactobacillus plantarum Lp90

Development stage: Unknown
Lead developer: BioGrowing
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus fermentum LF61 + Lactobacillus acidophilus LA85 + Lactobacillus plantarum Lp90 is a probiotic consortium consisting of three specific bacterial strains developed by BioGrowing (Shanghai Bio-Growing Co., Ltd.). This combination is primarily utilized in dietary supplements aimed at supporting the female urogenital microbiome and general gastrointestinal health. The mechanism of action involves the colonization of mucosal surfaces, where the strains produce antimicrobial metabolites such as lactic acid and hydrogen peroxide. These substances lower the local pH, creating an environment that inhibits the growth of opportunistic pathogens like *Candida albicans* and *Gardnerella vaginalis*. Additionally, these strains exhibit high mucosal adherence, which facilitates competitive exclusion of pathogenic bacteria and supports the restoration of a healthy microbial balance.

Brand names: Flora-Focus
Other names: Lactobacillus fermentum LF61 + Lactobacillus acidophilus LA85 + Lactobacillus plantarum Lp90L. fermentum LF61 + L. acidophilus LA85 + L. plantarum Lp90

Beyond the preview

Go deeper on lactobacillus fermentum LF61 + lactobacillus acidophilus LA85 + lactobacillus plantarum Lp90.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus fermentum LF61 + lactobacillus acidophilus LA85 + lactobacillus plantarum Lp90.

Explore the full profile